1. Noiri E, Tsukahara H; Parameters for Measurement of Oxidative Stress in Diabetes Mellitus: Applicability of Enzyme-Linked Immunosorbent Assay for Clinical Evaluation; J Investig Med. 2005; 4 167-175
2. Gregg L. Mayer, Sugaya T; Urinary L-FABP: A Novel Biomarker for Renal disease and Its Role in the Diagnosis and Prognosis of Chronic and Acute Kidney Disease; The Fats of Life. Winter 2006; Volume XX, No.1 4-12
3. Kamijo-Ikemori A, Sugaya T, Kimura K. Urinary Fatty Acid Binding Protein in Renal Disease. Clin Chim Acta. Jun 3, 2006
4. JM Thurman and CR Parikh. Peeking into the black box: New biomarkers for acute kidney injury. Kidney Int. 73: 379-381. 2008
5. Noiri E, Doi K, Negishi K, Tanaka T, Hamasaki Y, Fujita T, Portilla D, Sugaya T. Urinary fatty acid binding protein 1: An early predictive biomarker of kidney injury. Am J Physiol Renal Physiol. 296: 669-679, 2009
6. Doi K, Leelahavanichkul A, Yuen S.T.P, Star A.R. Animal models of sepsis and sepsis-induced kidney injury. J. Clin. Invest. 119: 2868-2878, 2009
7. McMahon BA, Murray PT. Urinary liver fatty acid-binding protein: another novel biomarker of acute kidney injury. Kidney Int. 2010 Apr; 77(8): 657-9.
8. Doi K, Noiri E, Sugaya T. Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care. Curr Opin Crit Care. 2010 Aug 21. [Epub ahead of print]
9. Lucchese B. A new urinary marker predicts progression to albuminuria and risk of death in patients with type 1 diabetes mellitus. Nature Reviews Nephrology 6: 445, 2010

1. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M; Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease; J Lab Clin Med. 2004; 143 23-30
2. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, Honda A, Okabe M, Fujino T, Hirata Y, Omata M, Kaneko R, Fujii H, Fukamizu A, Kimura K; Urinary Excretion of Fatty Acid-Binding Protein Reflects Stress Overload on the Proximal Tubules; Am J Pathol. 2004; 165 1243-1255
3. Ishimitsu T, Ohta S, Saito M, Teranishi M, Inada H, Yoshii M, Minami J, Ono H, Hikawa A, Shibata N, Sugaya T, Kamijo A, Kimura K, Ohrui M, Matsuoka H; Urinary excretion of liver fatty acid-binding protein in health-check participants; Clin Exp Nephrol. 2005; 9 34-39
4. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Kimura K; Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial; J Lab Clin Med. 2005; 145 125-133
5. Tsukahara H, Sugaya T, Hayakawa K, Mori Y, Hiraoka M, Hata A, Mayumi M; Quantification of L-type fatty acid binding protein in the urine of preterm neonates; Early Hum Dev. 2005; 81 643-646
6. Suzuki K, Murata H, Babazono T, Iwamoto Y; Clinical Significance of Urinary Liver-Type Fatty Acid-Binding Protein in Patients with Diabetic Nephropathy; Diabetes Care. 2005; 28 2038-2039
7. Nakamura T, Sugaya T, Ebihara I; Urinary Liver-Type Fatty Acid-Binding Protein: Discrimination between IgA Nephropathy and Thin Basement Membrane Nephropathy; Am J Nephrol. 2005; 25 447-450
8. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H; Effect of Pitavastatin on Urinary Liver-Type Fatty Acid-Binding Protein Levels in Patients with Early Diabetic Nephropathy; Diabetes Care. 2005; 28 2728-2732
9. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H; Candesartan ReducesUurinary Fatty Acid-Binding Protein Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease; Am J Med Sci. 2005; 330 (4) 161-165
10. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H; Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low density lipoprotein apheresis; Clin Nephrol. 2006; 65 (1) 1-6
11. Nakamura T, Sugaya T, Node K, Ueda Y, Koide H; Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in Contrast Medium-Induced Nephropathy; Am J Kidney Dis. 2006 (March); 47 (3) 439-444
12. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, TakagiM, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K; Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease; Molecular and Cellular Biochemistry. 2006
13. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K; Effect of Pitavastatin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Nondiabetic Mild Chronic Kidney Disease; Am J Nephrol. 2006; Mar 9; 26 (1) 82-86
14. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H; Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia; Am J Nephrol. 2006; Jun 13; 26: 276-280
15. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev. 22:385-389, 2006
16. Nakamura T, Sugaya T, Koide H. Cigarette Smoking Affects Urinary Liver-Type Fatty Acid-Binding Protein Concentration in Patients with Early Diabetic Nephropathy.　Diabetes Care. 29(7):1717, 2006
17. Kamijo-Ikemori A, Sugaya T, Obama A, Hiroi J, Miura H, Watanabe M, Kumai T, Ohtani-Kaneko R, Hirata K, Kimura K. Liver-type Fatty Acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction. Am J Pathol. 169(4):1107-1117, 2006
18. Nakamura T, Sugaya T, Koide H. Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure. Diabetologia 50(2):490-492, 2007
19. Negishi K, Noiri E, Sugaya T, Li S, Megyesi J, Nagothu K, Portilla D. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int. 72(3):348-358, 2007
20. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 333(6):321-326, 2007
21. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, Kimura K, Fujita T, Kinukawa T, Taniguchi H, Nakamura K, Goto M, Shinozaki N, Ohshima S, Sugaya T. Renal L-Type Fatty Acid-Binding Protein in Acute Ischemic Injury. J Am Soc Nephrol. 18:2894-2902, 2007
22. Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K. Beneficial Effects of Olmesartan and Temocapril on Urinary Liver-Type Fatty Acid-Binding Protein Levels in Normotensive Patients With Immunoglobin A Nephropathy. Am J Hypertens. 20:1195-1201, 2007
23. Portilla D, Dent C, Sugaya T, Nagothu KK, Kundi I, Moore P, Noiri E, Devarajan P. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. Dec 19; 2007
24. Tanaka T, Noiri E, Yamamoto T, Sugaya T, Negishi K, Maeda R, Nakamura K, Portilla D, Goto M, Fujita T. Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury. Nephron Exp Nephrol. 108:e19-e26, 2008
25. Negishi K, Noiri E, Maeda R, Portilla D, Sugaya T, Fujita T. Renal L-type fatty acid binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury. Kidney Int. 73(12): 1374-1384, 2008
26. Nakamura K, Ito K, Kato Y, Sugaya T, Kubo Y, Tsuji A. L-type Fatty Acid binding protein transgenic mouse as a novel tool to explore cytotoxicity to renal proximal tubules. Drug Metab Pharmacokinet. 23(4): 271-278, 2008
27. Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Node K. Renoprotective effect of telmisartan in patients with chronic kidney disease. Clin Exp Hypertens. 30(7): 662-672, 2008
28. Nakamura T, Inoue T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H, Node K. Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy. Clin Nephrol. 70(5): 385-392, 2008
    
29. Nakamura T, Sugaya T, Koide H. Urinary liver-type fatty acid-binding protein in septic shock – Effect of polymyxin B-immobilized fiber hemoperfusion. SHOCK 31(5):454-459, 2009
30. Kamijo-Ikemori A, Sugaya T, Sekizuka A, Hirata K, Kimura K. Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid binding protein transgenic mice. Nephrol Dial Transplant. 24(3): 788-800, 2009
31. Negishi K, Noiri E, Doi K, Mamiya R, Sugaya T, Portilla D, Fujita T. Monitoring of Urinary L-Type Fatty Acid-Binding Protein Predicts Histological Severity of Acute Kidney Injury. Am J Pathol. 174(4): 1154-1159, 2009
32. Tanaka T, Doi K, Maeda-Mamiya R, Negishi K, Portilla D, Sugaya T, Fujita T, Noiri E. Urinary L-Type Fatty Acid-Binding Protein Can Reflect Renal Tubulointerstitial Injury. Am J Pathol. 174(4): 1203-1211, 2009
33. Sasaki H, Kamijo-Ikemori A, Sugaya T, Yamashita K, Yokoyama T, Koike J, Sato T, Yasuda T, Kimura K. Urinary Fatty Acids and Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy. Nephron Clin Pract. 112(3): c148-c156, 2009
34. Yokoyama T, Kamijo-Ikemori A, Sugaya T, Hoshino S, Yasuda T, Kimura K. Urinary Excretion of Liver Type Fatty Acid Binding Protein Accurately Reflects the Degree of Tubulointerstitial Damage. Am J Pathol. 2009 May 12.[Epub ahead of print]
35. Nakamura T, Fujiwara N, Sugaya T, Ueda Y, Koide H. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy. Metabolism. 58(8): 1185-1190, 2009
36. Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P. Tubular and glomerular injyury in diabetes and the impact of ACE inhibition. Diabetes Care. 32(9): 1684-1688, 2009
37. von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, Bierhaus A, Humpert PM. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest. 40(2): 95-102, 2010.
38. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Sugaya T, Yamagishi S, Yamada S, Koide H. Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. Am J Med Sci. 339(2): 157-163, 2010.
39. Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P. Urinary liver-type fatty acid-binding protein (u-LFABP) predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care. 2010 Jun; 33(6): 1320 - 1324.
40. Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy. Kidney Blood Press Res. 2010 Jun 24; 33(3): 213 - 220.
41. Nakamura T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. Eur J Clin Invest. 40(9): 790-796, 2010
42. Doi K, Noiri E, Maeda-Mamiya R, Ishii T, Negishi K, Hamasaki Y, Fujita T, Yahagi N, Koide H, Sugaya T, Nakamura T. Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med. 2010 Jul 22. [Epub ahead of print]
43. Zuo N, Suzuki Y, Sugaya T, Osaki K, Kanaguchi Y, Wang L, Tomino Y. Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy. Nephrol Dial Transplant. 2010 Nov 25. [Epub ahead of print]
44. Matsui K, Kamijo-Ikemori A, Hara M, Sugaya T, Kodama T, Fujitani S, Taira Y, Yasuda T, Kimura K. Clinical significance of tubular and podocyte biomarkers in acute kidney injury. Clin Exp Nephrol. 2010 Dec 14. [Epub ahead of print]
45. Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S, Kaise R, Ishimitsu T, Tanaka Y, Kimura K. Clinical significance of Urinary Liver-Type Fatty Acid-Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients. Diabetes Care. 2011 March; 34: 691 – 696, 2011.
46. Matsui K, Kamijo-Ikemori A, Sugaya T, Yasuda T, Kimura K. Renal Liver-Type Fatty Acid Binding Protein (L-FABP) Attenuates Acute Kidney Injury in Aristolochic Acid Nephrotoxity. Am J Pathol. Vol.178,(3) 1021 –1032, 2011.

TOP